SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-364049"
 

Sökning: id:"swepub:oai:DiVA.org:uu-364049" > Apixaban compared t...

Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion : the EMANATE trial

Ezekowitz, Michael D. (författare)
Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA;Lankenau Heart Ctr, Wynnewood, PA 19096 USA;Bryn Mawr Hosp, Bryn Mawr, PA USA
Pollack, Charles V., Jr. (författare)
Thomas Jefferson Univ, Philadelphia, PA 19107 USA
Halperin, Jonathan L. (författare)
Icahn Sch Med, New York, NY USA
visa fler...
England, Richard D. (författare)
Pfizer, Groton, CT USA
Nguyen, Sandra VanPelt (författare)
Pfizer, Groton, CT USA
Spahr, Judith (författare)
Thomas Jefferson Univ, Philadelphia, PA 19107 USA
Sudworth, Maria (författare)
Pfizer, London, England
Cater, Nilo B. (författare)
Pfizer, New York, NY USA
Breazna, Andrei (författare)
Pfizer, New York, NY USA
Oldgren, Jonas, 1964- (författare)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi
Kirchhof, Paulus (författare)
Univ Birmingham, Inst Cardiovasc Sci, SWBH Trust, Birmingham, W Midlands, England;UHB NHS Trust, Birmingham, W Midlands, England
visa färre...
 (creator_code:org_t)
2018-04-06
2018
Engelska.
Ingår i: European Heart Journal. - : Oxford University Press (OUP). - 0195-668X .- 1522-9645. ; 39:32, s. 2959-2971
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Aim The primary objective was to compare apixaban to heparin/ vitamin K antagonist (VKA) in patients with atrial fibrillation (AF) and <= 48 h anticoagulation prior to randomization undergoing cardioversion. Methods One thousand five hundred patients were randomized. The apixaban dose of 5mg b.i.d. was reduced to 2.5 mg b.i.d. in patients with two of the following: age >= 80 years, weight <= 60 kg, or serum creatinine >= 133 mu mol/L. To expedite cardioversion, at the discretion of the investigator, imaging and/or a loading dose of 10 mg (down-titrated to 5 mg) was allowed. The endpoints for efficacy were stroke, systemic embolism (SE), and death. The endpoints for safety were major bleeding and clinically relevant non-major (CRNM) bleeding. Results There were 1038 active and 300 spontaneous cardioversions; 162 patients were not cardioverted. Imaging was performed in 855 patients, and 342 received a loading dose of apixaban. Comparing apixaban to heparin/VKA in the full analysis set, there were 0/753 vs. 6/747 strokes [relative risk (RR) 0; 95% confidence interval (95% CI) 0-0.64; nominal P = 0.015], no SE, and 2 vs. 1 deaths (RR 1.98; 95% CI 0.19-54.00; nominal P > 0.999). In the safety population, there were 3/735 vs. 6/721 major (RR 0.49; 95% CI 0.10-2.07; nominal P = 0.338) and 11 vs. 13 CRNM bleeding events (RR 0.83; 95% CI 0.34-1.89; nominal P = 0.685). On imaging, 60/61 with thrombi continued randomized treatment; all (61) were without outcome events. Conclusions Rates of strokes, systemic emboli, deaths, and bleeds were low for both apixaban and heparin/VKA treated AF patients undergoing cardioversion.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Nyckelord

Apixaban
Heparin/vitamin K antagonist
Cardioversion
Atrial fibrillation
Stroke
Anticoagulation
Cardiac imaging

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy